ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Losing Stock Guy: Why He Went Wrong
By Kevin Matras

Quote:

Search for Ticker

Free Membership

Search:

MYGN: Myriad Genetics Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

MYRIAD GENETICS INC (NASD)
MYGN	23.60	-0.21	(-0.88%)	Vol. 751,593	13:13 ET

Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products. They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. They have integrated these technologies using bioinformatics and robotics systems to conduct their research efforts on a high-throughput basis. This has enabled them to identify numerous proteins as targets for new drugs and molecular diagnostic tests.

General Information

MYRIAD GENETICS

320 Wakara Way Salt Lake City, UT 84108 Phone: 801 584-3600 Fax: 801 584-3640 Web: www.myriad.com Email: info@myriad.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	June
Last Reported Quarter	09/30/09
Next EPS Date	02/09/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	23.81
52 Week High	44.90
52 Week Low	22.38
Beta	0.29
20 Day Moving Average	2,130,595.50
Target Price Consensus	35.1

% Price Change
4 Week	-9.54
12 Week	-23.03
YTD	-28.76

% Price Change Relative to S&P 500
4 Week	-10.52
12 Week	-27.43
YTD	-41.04

Share Information
Shares Outstanding (millions)	96.10
Market Capitalization (millions)	2,268.03
Short Ratio	3.51
Last Split Date	03/26/2009

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	0.35
Current Year EPS Consensus Estimate	1.49
Estimated Long-Term EPS Growth Rate	23.30
Next EPS Report Date	02/09/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	2.25
30 Days Ago	2.15
60 Days Ago	2.25
90 Days Ago	2.25

Fundamental Ratios

P/E
Current FY Estimate:	15.89
Trailing 12 Months:	20.61
PEG Ratio	0.68

EPS Growth
vs. Previous Year	106.67%
vs. Previous Quarter	-16.22%

Sales Growth
vs. Previous Year	15.58%
vs. Previous Quarter:	-1.11%

Price Ratios
Price/Book	4.79
Price/Cash Flow	15.52
Price / Sales	6.61

ROE
09/30/09	22.61
06/30/09	19.39
03/31/09	25.22

ROA
09/30/09	21.10
06/30/09	17.83
03/31/09	22.75

Current Ratio
09/30/09	-
06/30/09	11.37
03/31/09	12.51

Quick Ratio
09/30/09	-
06/30/09	11.37
03/31/09	12.51

Operating Margin
09/30/09	33.13
06/30/09	29.46
03/31/09	30.68

Net Margin
09/30/09	44.63
06/30/09	41.79
03/31/09	30.87

Pre-Tax Margin
09/30/09	44.63
06/30/09	41.79
03/31/09	30.87

Book Value
09/30/09	4.92
06/30/09	4.53
03/31/09	6.15

Inventory Turnover
09/30/09	-
06/30/09	-
03/31/09	-

Debt-to-Equity
09/30/09	-
06/30/09	0.00
03/31/09	0.00

Debt to Capital
09/30/09	-
06/30/09	0.00
03/31/09	0.00


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research